Loading...
•
Jun 30, 2024
Structure Therapeutics Q2 2024 Earnings Report
Reported second quarter 2024 financial results and recent highlights.
Key Takeaways
Structure Therapeutics reported its second quarter 2024 financial results, highlighting a strong cash position of $927.1 million, which is expected to fund operations through at least 2027. The company is advancing its GSBR-1290 program with a Phase 2b study expected to start in Q4 2024 and anticipates selecting a development candidate for its amylin program in the same quarter.
GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024.
Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024.
Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors.
Strong financial position with cash balance of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027.
Structure Therapeutics
Structure Therapeutics
Forward Guidance
Structure Therapeutics is focused on advancing its GSBR-1290 program and expanding its pipeline of oral small molecule therapeutics for metabolic and cardiopulmonary diseases.
Positive Outlook
- GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024.
- Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024.
- Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors.
- Strong financial position with cash balance of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027.
- Advancing GSBR-1290 as rapidly as possible with the Phase 2b study expected to start before the end of the year.